Company Overview and News

8
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-06-22 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

33
Pernix Therapeutics Announces Result of Bid Process for Acquisition of Worldwide Rights to Contrave® for Weight Loss

2018-06-22 globenewswire
MORRISTOWN, N.J., June 22, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that Nalpropion Pharmaceuticals, Inc. (“Nalpropion”), the special purpose vehicle (“SPV”) created by Pernix and an investor group (collectively with Pernix, the “Investors”), has been informed by Orexigen Therapeutics, Inc. (“Orexigen”) that no other bids for Orexigen’s assets were received by the court-approved bid deadline.
OREXQ OREX PTX

16
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-06-06 sec.gov
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

11
Jaguar Health Appoints Robert J. Griffing Chief Commercialization Officer of Jaguar Subsidiary Napo Pharmaceuticals

2018-05-29 accesswire
SAN FRANCISCO, CA / ACCESSWIRE / May 29, 2018 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company"), a commercial stage natural-products pharmaceutical company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that the Company has appointed Robert J. Griffing, an accomplished pharmaceutical and biotech executive, as chief commercialization officer of Napo Pharmaceuticals, Inc.
JAGX OREXQ OREX

29
Pernix Therapeutics' (PTX) CEO John Sedor on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Pernix Therapeutics Holdings, Inc. (NYSEMKT:PTX) Q1 2018 Earnings Conference Call May 10, 2018 4:30 PM ET
OREXQ OREX PTX

16
OREX / Orexigen Therapeutics, Inc. 8-K (Current Report)

2018-05-04 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

10
OREX / Orexigen Therapeutics, Inc. FORM 8-K (Current Report)

2018-04-24 sec.gov
FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

20
Biotech Analysis Central Pharma News: Orexigen's Last Resort, Epizyme's Partial Clinical Hold, Eli Lilly And Incyte's Mixed Advisory Panel Vote

2018-04-24 seekingalpha
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry.
OREXQ OREX INCY EPZM PFE

34
Orexigen Enters into Agreement to Sell Company to Newly Formed Entity Nalpropion Pharmaceuticals

2018-04-24 biospace
One month after filing for bankruptcy anti-obesity company Orexigen Therapeutics, Inc. could be acquired by the newly-formed company Nalpropion Pharmaceuticals, Inc. for $75 million in cash.
OREXQ OREX PTX

7
BRIEF-Orexigen Therapeutics Enters Agreement For Sale Of Co

2018-04-23 reuters
* OREXIGEN THERAPEUTICS INC - ENTERED INTO ASSET PURCHASE DEAL WITH NALPROPION PHARMACEUTICALS, TO SELL SUBSTANTIALLY ALL OF ASSETS OF CO
OREXQ OREX

29
Pernix Therapeutics Announces Participation in Lead Bid for Acquisition of Worldwide Rights to Contrave® for Weight Loss

2018-04-23 globenewswire
MORRISTOWN, N.J, April 23, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced that it has agreed to participate in an investor group (collectively with Pernix, the “Investors”) that has entered into a “stalking horse” asset purchase agreement to acquire certain assets of Orexigen Therapeutics, Inc. (“Orexigen”), including worldwide rights to Contrave® (naltrexone HCl / bupropion HCl), a prescription-only weight loss medication, for $75 million in cash.
OREXQ OREX PTX

15
OREX / Orexigen Therapeutics, Inc. 8-K (Current Report)

2018-04-13 sec.gov
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549
OREX

Related Articles

HIMX: Himax Technologies Analysis and Research Report

7h - Asif

History and Development Himax Taiwan, its predecessor, was incorporated on June 12, 2001 as a limited liability company under the laws of the ROC. On April 26, 2005, the company established Himax Technologies Limited, an exempted company with limited liability under the Cayman Islands Companies Law, as a holding company to hold the shares of Himax Taiwan in connection with its reorganization and share exchange. On October 14, 2005, Himax Taiwan became its wholly owned subsidiary through a share exchange consummated pursuant to the ROC Business Mergers and Acquisitions Law through which the company acquired all of the issued and outstanding shares of Himax Taiwan, and the company issued ordinary shares to the shareholders of Himax Taiwan. Shareholders of Himax Taiwan received one of its ordinary shares in exchange for one Himax Taiwan common share. The share exchange was unanimously approved by shareholders of Himax Taiwan on June 10, 2005 with no dissenting shareholders and by ...

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

Silicon Investor Message Boards

This table lists all message boards related to OREX / Orexigen Therapeutics, Inc. on message board site Silicon Investor.

Stocks and Forex Analysis Orexigen - OREX
FOREX - Currency Trading LETu0027S PLAY IN THE FOREX..AND NOT GET LOST!
Isolyser (OREX)- Any comments ORXX - Orex Gold Mines Corporation
Forex Trading Strategies u0026 System Forex Forum
Precious Metal, FOREX and Commodity Trading--A little Ainu0027t Endorex (DOR)
CUSIP: 686164104